<div id="readability-page-1">08:29 AM EST, 11/26/2025 (MT Newswires) -- BioNTech (BNTX) said Wednesday that CureVac ( CVAC ) shareholders approved matters related to BioNTech's exchange offer at an extraordinary general meeting, with 99.16% voting in favor of the proposals.The exchange ratio has been set at 0.05363 of a BioNTech American depository share for each CureVac ( CVAC ) share, based on the 10-day volume-weighted average price of BioNTech ADSs through Nov. 25, 2025, the company said.BioNTech said it expects to complete the offer as soon as practicable. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

BNTX

BioNTech announced that CureVac shareholders approved the exchange offer with 99.16% voting in favor. The exchange ratio is set at 0.05363 BioNTech ADS for each CureVac share. BioNTech expects to complete the offer soon.

BioNTech Public Exchange Offer for CureVac Secures Shareholder Approval